Electrophysiological evaluation of retinal photoreceptor function after repeated bevacizumab injections

Documenta Ophthalmologica

Volumn 118, Issue 2, 2009, Pages 81-88

  Stahl, Andreas ^a   Feltgen, Nicolas ^a   Fuchs, Antje ^a   Bach, Michael ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Age related macular degeneration; Anti VEGF; Avastin; Bevacizumab; ERG; Toxicity

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN ANTIBODY;

ADULT; AGED; ARTICLE; CASE STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; ELECTROPHYSIOLOGY; ELECTRORETINOGRAPHY; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE REACTION; MALE; PHOTORECEPTOR; PROSPECTIVE STUDY; REPEATED DRUG DOSE; RETINA DISEASE; TREATMENT DURATION; VISUAL ACUITY;

EID: 61849167982     PISSN: 00124486     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10633-008-9136-7     Document Type: Article

References (21)

1. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363-372, e365
2. Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT et al (2007) Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 27:439-444. doi: 10.1097/ IAE.0b013e31804b3e15
3. Fulton AB, Rushton WA (1978) The human rod ERG: Correlation with psychophysical responses in light and dark adaptation. Vision Res 18:793-800. doi: 10.1016/0042-6989(78)90119-0
4. Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R, Temel SG (2007) Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 48:1773-1781. doi: 10.1167/iovs.06-0828
5. Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL et al (2006) Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: A short-term study. Retina 26:279-284. doi: 10.1097/00006982-200603000-00005
6. Jaissle GB, Ziemssen F, Petermeier K, Szurman P, Ladewig M, Gelisken F et al (2006) Bevacizumab for treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe 103:471-475. doi: 10.1007/ s00347-006-1355-2
7. Jorge R, Costa RA, Calucci D, Scott IU (2007) Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis. Graefes Arch Clin Exp Ophthalmol 245:1045-1048. doi: 10.1007/ s00417-006-0468-2
8. Lazarovici P, Marcinkiewicz C, Lelkes PI (2006) Cross talk between the cardiovascular and nervous systems: Neurotrophic effects of vascular endothelial growth factor (VEGF) and angiogenic effects of nerve growth factor (NGF)-implications in drug development. Curr Pharm Des 12:2609-2622. doi: 10.2174/138161206777698738
9. Lazic R, Gabric N (2007) Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245:68-73. doi: 10.1007/s00417-006-0466-4
10. Maturi RK, Bleau LA, Wilson DL (2006) Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 26:270-274. doi: 10.1097/00006982-200603000-00003
11. Michels S (2006) Is intravitreal bevacizumab (Avastin) safe? Br J Ophthalmol 90:1333-1334. doi: 10.1136/bjo.2006.102293
12. Moschos MM, Brouzas D, Apostolopoulos M, Koutsandrea C, Loukianou E, Moschos M (2007) Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: A preliminary multifocal-ERG and OCT study. Multifocal-ERG after use of bevacizumab in ARMD. Doc Ophthalmol 114:37-44. doi: 10.1007/s10633-006-9036-7
13. Ng EW, Adamis AP (2005) Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 40:352-368
14. Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK et al (2007) Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143:601-606. doi: 10.1016/j.ajo.2006.12.037
15. R Development Core Team (2007) R: A language and environment for statistical computing. Accessed 31 July 2006, from (http://www.R-project.org)
16. Severns ML, Johnson MA (1993) The care and fitting of Naka-Rushton functions to electroretinographic intensity-response data. Doc Ophthalmol 85:135-150. doi: 10.1007/BF01371129
17. Shetty R, Pai SA, Vincent A, Shetty N, Narayana KM, Sinha B, Shetty BK (2007) Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema. Doc Ophthalmol 116(2):129-135. doi: 10.1007/ s10633-007-9090-9)
18. Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA et al (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383-390. doi: 10.1097/00006982-200604000-00001
19. Stahl A, Agostini H, Hansen LL, Feltgen N (2007) Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Arch Clin Exp Ophthalmol 245:1429-1436. doi: 10.1007/s00417-007-0569-6
20. Wang Y, Galvan V, Gorostiza O, Ataie M, Jin K, Greenberg DA (2006) Vascular endothelial growth factor improves recovery of sensorimotor and cognitive deficits after focal cerebral ischemia in the rat. Brain Res 1115:186-193. doi: 10.1016/j.brainres.2006.07.060
21. Ziemssen F, Luke M, Messias A, Beutel J, Tatar O, Zrenner E, Bartz-Schmidt KU (2007) Safety monitoring in bevacizumab (Avastin) treatment: Retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol 28(2):101-109. doi: 10.1007/s10792-007-9122-1